Letrozol Stada

Letrozole, the active ingredient in Letrozol Stada, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of postmenopausal estrogen receptor‑positive breast cancer, reducing estrogen production that can drive tumor growth.

GNH USA supplies Letrozol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions. Customers benefit from reliable lead times and comprehensive technical support.

Letrozole is used in endocrine therapy targeting estrogen‑dependent breast cancer pathways. - Postmenopausal estrogen receptor‑positive breast cancer: reduces risk of disease recurrence and progression. - Adjuvant therapy for early‑stage ER+ breast cancer: helps prevent cancer return after surgery. - Metastatic ER+ breast cancer: slows tumor growth in advanced disease.

Letrozole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: sudden warmth and sweating. - Joint pain: aches in joints or muscles. - Fatigue: persistent tiredness. - Nausea: upset stomach and urge to vomit.

Serious or Rare Side Effects: - Severe liver injury: marked elevation of liver enzymes or hepatitis. - Bone fractures: increased risk of osteoporosis‑related breaks. - Pulmonary embolism: blood clot in lung vessels.

When prescribing Letrozol Stada, clinicians should consider several safety measures. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Assess bone health: evaluate bone mineral density and consider calcium/vitamin D supplementation. - Use only in postmenopausal women: drug is not indicated for premenopausal patients. - Review concomitant medications: check for drugs affecting CYP2A6 metabolism. - Contraindicated in pregnancy and lactation: discuss risks with prescriber. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Letrozol Stada can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent estrogen replacement therapy: may diminish letrozole’s efficacy. - Strong CYP2A6 inhibitors (e.g., fluvoxamine): increase letrozole plasma concentrations. - Strong CYP2A6 inducers (e.g., rifampicin): reduce letrozole exposure.

Moderate Interactions (Monitor Closely): - Tamoxifen: potential antagonistic effect; monitor therapeutic response. - Warfarin: possible alteration of INR; check coagulation parameters regularly.